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CSF1 receptor blockade by inducing PMN-MDSC infiltration of
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Summary
Tumor associated macrophages (TAM) contribute to all aspects of tumor progression. Use of
CSF1R inhibitors to target TAM is therapeutically appealing, but has had very limited antitumor
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effects. Here, we have identified the mechanism that limited the effect of CSF1R targeted therapy.
We demonstrated that carcinoma associated fibroblasts (CAF) are major sources of chemokines
that recruit granulocytes to tumors. CSF1 produced by tumor cells caused HDAC2-mediated
down-regulation of granulocyte-specific chemokine expression in CAF, which limited migration of
these cells to tumors. Treatment with CSF1R inhibitors disrupted this cross talk and triggered a
profound increase in granulocyte recruitment to tumors. Combining CSF1R inhibitor with a
CXCR2 antagonist blocked granulocyte infiltration of tumors and showed strong anti-tumor
effects.

In Brief

Author Manuscript

Kumar et al. show that CSF1R inhibition alters chemokine secretion by cancer associated
fibroblasts, which attracts pro-tumor PMN-MDSCs and results in poor efficacy. Combined
inhibition of CSF1R and CXCR2 blocks MDSC recruitment and reduces tumor growth, which is
further improved by the addition of anti-PD-1.

Author Manuscript
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Introduction
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Myeloid cells are critical components of the tumor microenvironment, and contribute to all
aspects of tumor progression. These cells are comprised of tumor-associated macrophages
(TAM), polymorphonuclear myeloid-derived suppressor cells, (PMN-MDSC), monocytic
MDSC (M-MDSC), and dendritic cells (DC) (Gabrilovich et al., 2012; Grivennikov et al.,
2010). There is now ample evidence that TAM and MDSC exert their pro-tumorigenic
effects by suppressing T-cell functions and promoting tumor angiogenesis, proliferation,
survival, and metastasis (Coussens and Pollard, 2011; Talmadge and Gabrilovich, 2013).
CSF1(M-CSF)/CSF1R signaling is a key regulator of TAM differentiation and survival (Lin
et al., 2001; Pixley and Stanley, 2004). CSF1R is a receptor tyrosine kinase that undergoes
oligomerization and auto-phosphorylation upon binding to its ligands (CSF1 or IL-34). Mice
lacking functional CSF1 ligands or receptors have significantly diminished macrophage
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populations (Guleria and Pollard, 2001). Consequently, targeting TAM by blocking the
CSF1/CSF1R pathway has generated significant interest in recent years and there are a
number of ongoing or recently completed clinical studies targeting this pathway (Ries et al.,
2015). So far, clinical successes have been limited only to patients with diffuse-type giant
cell tumor, which is characterized by translocations of chromosome 1 involving the CSF1
gene (Ries et al., 2014; Tap et al., 2015). However, in these patients, CSF1R inhibitors
directly targeted tumor cells. Other clinical study examples include Hodgkin’s lymphoma
patients treated with single agent PLX3397 (Butowski et al., 2016) and relapsed or
refractory Hodgkin lymphoma patients who have been treated with a CSF1R inhibitor,
JNJ-40346527 (Sasse et al., 2016).

Author Manuscript

In preclinical models, various small molecule inhibitors, such as Ki20227 (Ohno et al.,
2006), PLX3397 (Mitchem et al., 2013; Mok et al., 2015; Sluijter et al., 2014), GW2580
(Conway et al., 2005), and BLZ945(Strachan et al., 2013), and antibodies, such as 5A1
(Lokeshwar and Lin, 1988), M279(MacDonald et al., 2010) have been studied in blocking
the CSF1/CSF1R pathway. However, none of these single agent treatments showed
therapeutic benefits. In the study where CSF1R inhibitor (BLZ945) did show regression of
established tumors and increased survival in a mouse proneural glioblastoma multiforme
model, no depletion of TAM was observed (Pyonteck et al., 2013). It remains unclear why
the rather potent depletion of TAM in various tumor models has failed to deliver an
antitumor effect. Recently, the focus has shifted to using combinations of CSF1R inhibitors
with various other agents. Treatment with PLX3397 in combination with paclitaxel
improved survival of mammary tumor-bearing mice (DeNardo et al., 2011b). In preclinical
models of prostate cancer, PLX3397 treatment in combination with radiation therapy
demonstrated an augmented and more durable response than irradiation alone (Xu et al.,
2013). PLX3397 improved the efficacy of adoptive cell transfer immunotherapy in mouse
melanoma models (Mok et al., 2014; Sluijter et al., 2014). PLX3397 treatment in pancreatic
cancer models upregulated T-cell checkpoint molecules, specifically PD-L1 and CTLA-4,
which restrained antitumor effect. When combined with PD1 and CTLA-4 antagonists,
PLX3397 treatment elicited potent tumor regressions (Zhu et al., 2014).

Author Manuscript

Although data on combination therapy are encouraging, a lack of understanding of the
mechanism that regulates tumor progression, even with substantial depletion of TAM, raised
concerns regarding the potential clinical utility of these therapeutic strategies. The goal of
this study was to understand the mechanism of the effects of CSF1R inhibitors on tumor
progression.

Author Manuscript

Results
Inhibition of CSF1R signaling induces accumulation of PMN-MDSC in tumors
To elucidate the mechanism of CSF1R inhibition effect on microenvironment and tumor
progression and we used a selective CSF1R inhibitor JNJ-40346527 (Genovese et al., 2015;
Huang et al., 2013) given daily via oral administration (20 mg/kg). To test its effect on tumor
growth we used subcutaneous C57BL6 mouse models of melanoma (B16F10), lung
carcinoma (LLC), lymphoma (EL-4) and BALB/c models of colon carcinoma (CT26) and
breast carcinoma (4T1). Treatment started one day after tumor inoculation and continued for
Cancer Cell. Author manuscript; available in PMC 2018 November 13.
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4–5 weeks. In addition, an orthotopic model of lung cancer (LLC), transgenic Ret melanoma
and TRAMP prostate cancer models were used The transgenic Ret melanoma model is
based on the expression of the human RET oncogene in melanocytes, which results in
spontaneous development of melanoma metastasizing to different organs (Kato et al., 1998).
Ret mice were treated starting at two months of age. In the TRAMP model of prostate
cancer SV40 large T antigen is expressed in the prostatic epithelium (Greenberg et al.,
1995). In this model, treatment was started at 5 months of age. In most tumor models,
treatment with JNJ-40346527 did not delay tumor progression (Fig. 1A). However, this
CSF1R inhibitor did have the expected effect on CD11b+F4/80+Gr-1− TAM. In all tested
models, the proportion of TAM among CD45+ cells hematopoietic cells was dramatically
reduced (Fig. 1B, Fig. S1A). While no significant difference was seen in the proportion of
CD11b+Ly6ChiLy6G− monocytic cells (Fig. 1C), the proportion of CD11b+Ly6CloLy6G+
granulocytic cells was significantly increased (Fig. 1D). Granulocytes isolated from tumor
tissues of JNJ-40346527 treated mice had potent immune suppressive activity (Fig. 1E),
which characterized these cells as PMN-MDSC. Increase in PMN-MDSC was not the result
of just a re-distribution between the proportions of myeloid cells, since treatment of mice
with JNJ-40346527 significantly increased the absolute number of PMN-MDSC adjusted to
tumor weight (Fig. 1F). In two models (LLC and EL-4) we also evaluated the presence of
granulocytes by immunohistochemistry. Treatment with CSF1R inhibitor caused a
significant increase in Ly6G+ granulocytes (Fig. S1B,C).

Author Manuscript

To evaluate the effect of JNJ-40346527 on palpable tumors, the treatment was started 10
days after tumor cell injection. After two weeks of JNJ-40346527 treatment PMN-MDSC
were significantly increased in tumor-bearing (TB) mice (Fig. S1D). To make sure that the
observed effect was not unique to JNJ-40346527, we treated LLC TB mice with CSF1R
(CD115) antibody. CD115 antibody did not affect tumor progression (Fig. S1E), but caused
a significant decrease in TAM and a significant increase of tumor PMN-MDSC (Fig. S1F).
Thus, while inhibition of CSF1R caused substantial decrease in TAM, it was also associated
with accumulation of PMN-MDSC in tumors.
Inhibition of CSF1R caused recruitment of PMN-MDSC to tumors

Author Manuscript

We observed only a small increase in the frequency of granulocytic cells in the bone marrow
(BM), spleen (SP), or peripheral blood of mice treated with JNJ-40346527 (Fig. 2A) and
CD115 antibody (Fig. S1G). No significant increase of monocytic cells was evident in BM
and SP (Fig. S1H). Enriched hematopoietic progenitor cells (HPC) were cultured with GMCSF and JNJ-40346527 with and without tumor explant supernatants (TES). Three-day
treatment in the absence (Fig. S2A,B) or presence (Fig. S2C,D) of TES did not affect
differentiation of myeloid cells, whereas after 6 days in culture JNJ-40346527 caused a
significant decrease in the presence of macrophages, but had little effect on granulocytic
cells (Fig. S2E,F).
We next investigated the kinetics of changes in myeloid cells in LLC TB mice. In this
model, treatment with JNJ-40346527 did not significantly affect tumor growth until day 16.
By day 23 tumor size in the treated group was significantly higher than in untreated mice
(Fig. 1A). JNJ-40346527 caused a decrease in the presence of TAM only by day 23 (Fig.
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2B). Tumor progression in untreated mice was associated with accumulation of PMNMDSC in the tumor, SP and BM (Fig. 2C–F). Eight-day treatment with JNJ-40346527
resulted in a small but significant increase in the presence of PMN-MDSC in tumors. This
increase became larger by day 16, and further increased by day 23 (Fig. 2B). In contrast,
JNJ-40346527 induced accumulation of PMN-MDSC in SP and BM only by day 23 when
tumors in the treated group were significantly larger than in untreated mice (Fig. 2C,D).
Similarly, JNJ-40346527-induced accumulation of M-MDSC in spleens and BM was
evident only on day 23 (Fig. 2E,F). JNJ-40346527 increased the number of common
myeloid progenitors and granulocyte-macrophage progenitors in BM only by day 23 (Fig.
S3A). There was no significant difference in BM CFU-GM colonies on day 9 between
untreated and JNJ-40346527 treated mice and a small increase in colonies was observed on
day 16 (Fig. S3B). Taken together, these results indicate that JNJ-40346527 induced
accumulation of PMN-MDSC in the tumor site was not the result of initial expansion of
these cells in BM and SP, and that this accumulation preceded accelerated tumor
progression.
Mechanism of CSF1R inhibitor mediated PMN-MDSC recruitment to tumors

Author Manuscript
Author Manuscript

In an attempt to understand the mechanism of PMN-MDSC migration to tumor sites, we
collected tumors from control and JNJ-40346527 treated LLC TB mice and evaluated
expression of various chemokines in tumor cell lysates. We observed significant upregulation of most chemokines responsible for granulocyte recruitment (Fig. 3A). Similar
results were seen in the TRAMP model (Fig. 3B). Some of the chemokines were not specific
to granulocytes and could recruit monocytic cells and macrophages. More detailed studies
were performed with Cxcl-1, which plays a major role in recruitment of neutrophils and
PMN-MDSC to tumor site (Noman et al., 2015; Obermajer et al., 2011). Proteins
concentrations were measured in LLC tumor lysates at different times during the treatment.
After 9 days, JNJ-40346527 caused modest but significant up-regulation of Cxcl-1, this
difference became more pronounced by day 16. By day 23 this difference decreased, which
correlated with a substantial increase in tumor size in the untreated mice (Fig. 3C).
PDGFRα+ carcinoma associated fibroblasts (CAF), CD45+CD11b+ myeloid cells, and
CD45−EPCAM+ tumor cells were sorted directly from LLC tumors on day 16 after
inoculation and the amount of Cxcl-1 was measured in cell lysates by ELISA. CAF were
found to be the major producers of Cxcl-1 (Fig. 3D). Treatment with CSF1R inhibitor did
not affect the amount of Cxcl-1 secreted by tumor or myeloid cells but did cause increased
release of Cxcl-1 by CAF (Fig. 3E). A similar effect was observed in CAF in CD115
antibody treated mice (Fig. 3F). Three-week treatment of LLC TB mice with JNJ-40346527
caused decrease in the expression of CXCR2 (a major Cxcl-1 receptor on granulocytes) on
BM granulocytes, but the receptor expression remained unchanged in the EL-4 and B16F10
model (Fig. S3C). CSF1R inhibitor did not affect the proportion of CAF in the tumor
microenvironment.
To test whether CAF could be directly involved in the recruitment of PMN-MDSC to the
tumors, we evaluated archived tumor tissues from mice with 4662 pancreatic ductal
adenocarcinoma (PDA) treated with fibroblast activation protein (FAP) - specific CAR-T
cells, which selectively target and deplete CAF. FAP CAR-T cells had been shown to reduce
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tumor growth in these mice (Lo et al., 2015; Wang et al., 2014). Tumors were collected 3
days after the injection of a second dose of FAP-CAR-T cells. We found that FAP-CAR-T
cell induced depletion of CAF was associated with significant reduction in Cxcl1 mRNA in
tumors (Fig. 3G) and a significant decrease in the presence of PMN-MDSC (Fig. 3H). Since
treatment with FAP-CAR-T cells substantially reduced tumor growth in mice, it was
possible that observed changes in tumor PMN-MDSC were due to decreased tumor burden
and not CAF depletion. To address this concern, we conducted a separate set of experiments
in which we evaluated samples collected 3 days after initial FAP-CAR-T cells
administration. We found that the number of PMN-MDSC significantly decreased (Fig. 3I).
We also found significant decrease in expression of Cxcl1 in the tumors (Fig. 3J).

Author Manuscript
Author Manuscript
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These data suggested that CAF could be important for PMN-MDSC migration to tumor
sites. How could CSF1 regulate cytokine production by fibroblasts? First, we used primary
lung fibroblasts isolated from naïve mice (Fig. S4A). We found that these cells expressed
detectable CSF1R protein on the cell surface and cytoplasm (Fig. 4A), and also expressed
Cxcl1 mRNA and Cxcl1 protein (Fig. 4B). Treatment of these cells with CSF1 caused upregulation of CSF1R (Fig. 4A) and significant reduction of Cxcl1. This effect was abrogated
when JNJ-40346527 was added during the last 48 hr of culture (Fig. 4B). To investigate
whether this effect translated to PMN-MDSC migration, we isolated PMN-MDSC from BM
of LLC TB mice. Supernatants were prepared from lung fibroblasts cultures treated with
CSF1 with or without JNJ-40346527 and then were used in neutrophil migration assays.
Supernatant from untreated fibroblasts caused robust migration of PMN-MDSC. CSF1
significantly reduced PMN-MDSC migration, but this effect was completely reversed by
JNJ-40346527 (Fig. 4C). Treatment of BM PMN-MDSC with CSF1 did not change the
expression of CXCR2 (Fig. S4B). CSF1 neutralizing antibody abrogated the inhibitory
effect of CSF1 on fibroblast mediated PMN-MDSC migration (Fig. 4D). To confirm a
specific role of Cxcl1 in this process, we used Cxcl-1 neutralizing antibody, which
dramatically reduced PMN-MDSC migration caused by fibroblasts. Cxcl1 antibody
abrogated the effect of JNJ-40346527 on PMN-MDSC migration (Fig. 4E), thus directly
implicating Cxcl1 in PMN-MDSC migration induced by CSF1R inhibition. To determine the
specific nature of CSF1 effect on Cxcl1 production by fibroblasts, we evaluated PMNMDSC migration to recombinant Cxcl1 in the absence of supernatants from fibroblasts.
Cxcl-1 caused a potent chemotactic effect on PMN-MDSC. However, this effect was not
regulated by the addition of CSF1 or JNJ-40346527 (Fig. 4F). To test whether CSF1R
inhibition affected the tumor microenvironment in vivo, LLC tumors were excised 14 days
after the treatment of mice with JNJ-40346527. Tumor explant supernatants (TES) were
prepared and tested in neutrophil migration assays. Despite the fact that TES from
JNJ-40346527 treated mice had higher amounts of CSF1 (Fig. 4G), these TES caused
significantly higher neutrophil migration than the TES from vehicle treated mice (Fig. 4H).
To clarify the role of PMN-MDSC migration in the JNJ-40346527 mediated effect in the
tumor microenvironment in vivo, lethally irradiated recipient wild-type (WT) mice were
reconstituted with BM from either WT or CXCR2 KO donor mice. Six weeks after
reconstitution, the absence of CXCR2 expression on neutrophils was confirmed (Fig. S4C),
and LLC cells were injected. Mice were treated with JNJ-40346527 for 12 days. In contrast
to all other groups where tumors grew progressively; mice reconstituted with CXCR2-KO
Cancer Cell. Author manuscript; available in PMC 2018 November 13.
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BM and treated with JNJ-40346527 had dramatically reduced tumor growth (Fig. 4I). While
JNJ-40346527 caused significant increase in the presence of PMN-MDSC in WT BM
recipients, in CXCR2 KO BM recipient, the presence of PMN-MDSC was practically
undetectable (Fig. 5J) as anticipated (Chao et al., 2016). TAM were significantly decreased
in all JNJ-40346527 treated mice (Fig. 5J).

Author Manuscript

Tumor cells expressed much higher amounts of Csf1 than CAF (Fig. S4D). Expression of
Csf1 varied between different tumors with LLC cells expressing the highest level of Csf1
among tested cell lines (Fig. S4E). To verify the role of CSF1 in PMN-MDSC recruitment in
vivo, we deleted Csf1 in LLC tumor cells using CRISPR/CAS9 technology (Fig. S4F). LLC
clone lacking CSF1 production (Fig. S4G) was injected s.c. into the mice. Tumor cells with
deleted Csf1 had delayed growth kinetics, but tumors still grew progressively (Fig. S4H).
Mice with WT and Csf1 deleted tumors were sacrificed when tumors were of similar sizes
and the presence of PMN-MDSC and chemokine profiles were measured. Lack of CSF1 in
tumor cells resulted in a dramatic reduction of TAM but a significant increase in tumor
PMN-MDSC (Fig. 5A). Deletion of Csf1 resulted in up-regulation of gene expression of
several chemokines involved in granulocyte recruitment including Cxcl1 (Fig. 5B).
Supernatant from WT but not from Csf1 deficient LLC inhibited migration of PMN-MDSC
(Fig. 5C).
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To verify the role of Csf1R in fibroblasts, we down-regulated this receptor in primary mouse
lung fibroblasts using lentiviral shRNA constructs (Fig. S5A,B). Csf1 induced inhibition of
PMN-MDSC migration was abrogated in fibroblasts transduced with Csf1R shRNA (Fig.
5D), and the same results were obtained with two different shRNA constructs. To test the
role of CSF1R in fibroblasts in vivo, mice were injected s.c. with LLC and control or CSF1R
silenced fibroblasts mixed with tumor cells at 1:1 ratio. Twelve days later, the absolute
number of myeloid cells was counted per gram of tumor. CSF1R silenced fibroblasts did not
affect the number of TAM and M-MDSC in tumors, but significantly increased the presence
of PMN-MDSC (Fig. 5E).

Author Manuscript

We asked whether similar phenomena are also observed with CAFs. CAFs were isolated
from LLC tumors and cultured with CSF1 with and without JNJ-40346527 or CSF1
antibody. CSF1 caused significant reduction in CXCL1 production, which was abrogated by
both JNJ-40346527 and CSF1 antibody (Fig. S5C,D). Csf1 significantly inhibited CAF
induced neutrophils migration. This inhibition was abrogated by JNJ-40346527 and by Csf1
antibody (Fig. S5E,F). We down-regulated Csf1R in CAFs using shRNA (Fig. S5G) and
found that it cancelled CSF1 induced inhibition of neutrophil migration (Fig. S5H). Thus,
tumor cells-derived CSF1 negatively regulated the production of chemokines recruiting
PMN-MDSC to the tumor site by CAF. Inhibition of CSF1R signaling eliminated this downregulation and caused accumulation of PMN-MDSC in tumors.
Regulation of human neutrophil’s migration by CSF-R inhibitor
To assess the above described mechanism in humans, we evaluated tumors from 4 cancer
patients within 3 hr after surgical resection. Expression of CSF1R was evaluated in
CD45+CD3+ T lymphocytes, CD45+CD163+ TAM, and CD45−FAP+ CAF (Fig. S5I). In all
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4 patients CAF clearly demonstrated detectable surface expression of CSF1R. In contrast, T
cells were negative for CSF1R. TAM had higher expression of CSF1R than CAF (Fig. 5F).
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CAF were isolated from resected lung tissues of patients with non-small cell lung cancer
(NSCLC) and were treated for 4 days with CSF1 followed by JNJ-40346527 for an
additional 2 days. Fibroblasts expressed high levels of Cxcl8 – a major chemokine
regulating migration of human neutrophils. CSF1 dramatically reduced its expression but
JNJ-40346527 completely reversed this effect (Fig. 5G). Supernatant from fibroblasts treated
as described above were used to stimulate the migration of neutrophils isolated from
peripheral blood of healthy donors. Treatment of fibroblasts with CSF1 significantly reduced
the ability of the supernatants to attract neutrophils, whereas JNJ-40346527 completely
abrogated this effect (Fig. 5H). Importantly, in the absence of fibroblast supernatants neither
CSF1, nor CSF1R inhibitor induced neutrophil migration (Fig. 5H). Adding a neutralizing
CXCL8 antibody significantly reduced fibroblast-induced neutrophil migration and
abrogated the effect of JNJ-40346527 on neutrophil migration (Fig. 5I).

Author Manuscript
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To confirm the role of CSF1R in the regulation of human fibroblasts ability to attract
neutrophils, the expression of the receptor was silenced using lentiviral shRNA constructs
(Fig. S5J,K). Silencing of CSF1R in human fibroblasts abrogated the ability of CSF1 to
suppress neutrophil migration by these cells (Fig. 6A). CXCL8 had potent activity to attract
neutrophils. In the absence of fibroblast supernatants, neither CSF1 nor the combination of
CSF1 with JNJ-40346527 affected neutrophil migration to CXCL8 (Fig. 6B). These data
strongly suggested that in humans, CSF1 and CSF1R inhibitor could regulate fibroblastmediated neutrophil migration. To determine a possible link between CXCL8, CSF1, and the
accumulation of PMN-MDSC in the tumors of cancer patients, we collected samples from
patients with colorectal cancer, breast cancer, and NSCLC. Populations of CD11b
+CD14−CD15+ PMN-MDSC and CD14+HLA-DR−/lo M-MDSC in CD45+ hematopoietic
cells from tumors were evaluated and CXCL8 and CSF1 proteins were measured in tumor
lysates. Samples were split based on the median of CXCL8 amount. The presence of PMNMDSC in the samples with CXCL8 level above the median was 5-times higher than in
samples with CXCL8 level below the median (Fig. 6C). In contrast, no such correlation was
found in the level of M-MDSC (Fig. 6D). In addition, no connection was observed between
CXCL8 level in tumors and the presence of PMN or M-MDSC in peripheral blood in these
patients (Fig. S6A). A similar analysis was performed for CSF1 but the results were
reversed. The presence of PMN-MDSC in tumor samples with a CSF1 concentration above
the median was 3 times lower than in samples with CSF1 level below the median (Fig. 6E).
Again, no differences were observed in the presence of M-MDSC (Fig. 6F) and CSF1
amounts in tumor tissues did not correlate with the presence of PMN- or M-MDSC in
peripheral blood (Fig. S6B). The level of CSF1 inversely related with the amount of CXCL8
in tumor tissues (Fig. 6G). These data indicate that in patients with at least 3 types of cancer
lower amount of CSF1 in tumor tissues were associated with the increased production of
CXCL8 and accumulation of PMN-MDSC.
We verified this conclusion in different experimental systems. First, we evaluated the
secretomes from 15 freshly isolated ovarian tumors, which included all major subtypes. We
found a highly significant inverse correlation between the CXCL8 and CSF1 proteins (Fig.
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6H). Since we have recently identified LOX-1 as a marker of human PMN-MDSC, which
allows for detection of these cells in tumor tissues using immune fluorescent microscopy
(Condamine et al., 2016), we then tested the clinical significance of LOX-1+CD15+ PMNMDSC in tissue microarray (TMA) obtained from patients with head and neck cancer. The
presence of PMN-MDSC was significantly associated with shorter survival in these patients
(Fig. 6I). Using this TMA we also tested the link between the presence of PMN-MDSC and
tissue CSF1 protein by immunohistochemistry (Fig. S6C). To quantify the association of
CSF1 in tumors with the presence of PMN-MDSC, all samples were split into two groups
based on the median level (160) of CSF1 expression evaluated using the H-score of intensity
and percentage of positive cells. PMN-MDSC abundance in samples with above the median
expression of CSF1 was significantly lower than in samples with lower than median
expression of CSF1 (Fig. 6J). We evaluated de-convoluted neutrophil and monocyte
signatures (Newman et al., 2015) in >19,000 samples from molecular profiling tumor
database (Merck & Co., Inc., Kenilworth, NJ USA). These signatures were correlated with
the expression of CSF1 and CSF2. Higher expression of CSF1 was associated with lower
presence of cells with neutrophil signature (Fig. 6K, quadrants III and IV). The higher
expression of CSF1 was associated with increased presence of cells with a monocyte
signature (quadrants I and III). In contrast expression of CSF2 (which encodes GM-CSF)
was associated with increased presence of cells with neutrophil signature (quadrants III and
IV) (Fig. 6K). These results confirmed that CSF1 expression was negatively associated with
the presence of PMN-MDSC in tumor tissues.
Mechanisms regulating inhibition of chemokines production by CSF1
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To investigate the mechanism of CSF1R mediated regulation of Cxcl1 expression, we looked
at the role of histone deacetylases (HDAC). Mouse fibroblasts were cultured for 6 days with
CSF1 in the presence of entinostat, a class I HDAC inhibitor. CSF1 dramatically reduced
Cxcl1 expression and Cxcl1 released by these cells. Entinostat completely abrogated this
effect (Fig. 7A). To test this effect in vivo, LLC TB mice were treated with entinostat (10
mg/kg, p.o.) daily for 10 days starting from day 15 after tumor inoculation. Entinostat
treatment induced substantial increase in the expression of several granulocyte-specific
chemokines including Cxcl1 (Fig. 7B). Treatment of mice with entinostat despite causing
increase in the amount of CSF1 in tumor cells (Fig. 7C), strongly up-regulated Cxcl1 in
CAF (Fig. 7D). Entinostat did not affect the expression of CSF1R in CAF (Fig. 7E), and was
associated with increased infiltration of tumor tissues by PMN-MDSC but not TAM in LLC
and CT-26 tumor models (Fig. 7F).
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To identify the specific HDAC that is recruited to the Cxcl1 promoter, we used a ChIP assay.
CSF1 caused a significant decrease in the recruitment of acetylated H3 histone to cxcl-1
promoter. This decrease was completely reversed by entinostat (Fig. 7G). CSF1 induced
significant increase in the recruitment of HDAC2 to Cxcl1 promoter (Fig. 7H), whereas no
binding of HDAC1 was detected (data not shown). Thus, CSF1 caused recruitment of
HDAC2 to Cxcl1 promoter, which silenced Cxcl1 expression.
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We hypothesized that the combination of CSF1R inhibitor with an inhibitor of granulocyte
recruitment may have therapeutic effect. Because CXCR2 is the receptor for most
chemokines up-regulated by the CSF1R inhibitor (including Cxcl-1), we used a selective
inhibitor of CXCR2 (SB225002). Mice with established LLC or B16F10 tumors were
treated with JNJ-40346527, SB225002 or combination of both. As expected, neither of the
inhibitors alone had significant antitumor effect. However, the combination of inhibitors
resulted in a highly significant delay in tumor progression in both cancer models (Fig. 8A).
The presences of TAM and PMN-MDSC were evaluated in B16F10 tumors. Combined
treatment abrogated JNJ-40346527 induced accumulation of PMN-MDSC, while
maintaining decreased presence of TAM (Fig. 8B). We wanted to know whether two
inhibitors provided additional therapeutic benefits if combined with check-point inhibitor, so
we treated LLC TB mice with the combination of inhibitors and PD-1 antibody. The PD-1
antibody alone had a weak therapeutic effect and combination of PD-1 antibody with
JNJ-40346527 or SB225002 did not enhance antitumor effect. However, the combination of
the two inhibitors together with PD-1 antibody resulted in a dramatic antitumor effect (Fig.
8C).

Discussion
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In an attempt to elucidate a mechanism that limits the antitumor activity of CSF1R inhibitor,
we have identified a crosstalk between tumor cells and CAF that limits the recruitment of
PMN-MDSC to tumors. Fibroblasts are the key cells regulating multiple biological
processes, including inflammation, wound healing, and tissue remodeling, and are intimately
involved in tumor progression (Fearon, 2014; Gascard and Tlsty, 2016). CAF differentiate
from pre-existing normal fibroblasts, myofibroblasts, preadipocytes, smooth muscle cells, or
BM derived progenitors. Tumor cells activate stromal fibroblasts or recruited mesenchymal
stem cells to become CAFs, which release a variety of chemokines that promote tumor
growth and metastasis (Mishra et al., 2011). There is now ample evidence that CAF produce
a large array of chemokines, including the ones specific for granulocytes, such as CXCL1
(Feig et al., 2013; Orimo and Weinberg, 2006). It has recently been reported that CAF also
promote migration of monocytic cells to tumors (Yang et al., 2016), but the direct effect of
fibroblasts on neutrophil migration has not been previously demonstrated. In our study,
PMN-MDSC recruitment by CAF is consistent with the ability of CAF to produce
granulocytic chemokines. However, this was not consistent with the observations that
granulocytic infiltration of tumors is usually not very strong. In most types of cancer,
granulocytes are present in smaller numbers than TAM and monocytic cells (DeNardo et al.,
2011a; Kumar et al., 2016). Our data suggest an explanation for this phenomenon. Cxcl1
expression is down-regulated by CSF1, which is produced by many tumor cells (Lucas et al.,
2008). This limits the migration of PMN-MDSC to the tumor site. In this study, we focused
on Cxcl1 as the most important chemokine for granulocytic migration. However, it is likely
that similar effects could be observed for other granulocytic chemokines as well.
In humans, CXCL1 is not a potent granulocytic chemokine. Instead, this role is played by
CXCL8, but it appears that CSF1 has similar effects on human fibroblasts. More
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importantly, CSF1 levels in human tumors were inversely correlated with the presence of
PMN-MDSC in tumors. This effect was not observed for M-MDSC, which demonstrates the
specific nature of this interaction.
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It is now known that PMN-MDSC contribute to tumor progression by inhibiting immune
responses and promoting tumor angiogenesis, tumor cell invasion, metastasis, etc.
(Gabrilovich, 2017). Ample evidence now supports a close association between MDSC
accumulation in peripheral blood and clinical outcome in cancer patients (Messmer et al.,
2015; Solito et al., 2014). A recent meta-analysis of 442 patients with various solid tumors
demonstrated that peripheral blood MDSC were significantly associated with poor overall
and progression-free survival (Zhang et al., 2016a). MDSC have also been implicated in
resistance to anti-cancer therapies, including sunitinib (Finke et al., 2011), cisplatin, and
other chemotherapeutics in lung cancer (Vetsika et al., 2014), and doxorubicin and
melphalan in multiple myeloma (Ramachandran et al., 2016). Recent studies showed an
association of a lower presence of MDSC with positive patient clinical responses to
ipilimumab (Meyer et al., 2014) and PD-1 antibodies (Weber et al., 2016).
In human tumor tissues, CD15 or CD66b markers encompass both neutrophils and PMNMDSC in human tumor tissues. Accumulation of these cells was associated with negative
outcomes in a number of human cancers, including gallbladder carcinoma (GBC) (Zhang et
al., 2016b), cholangiocarcinoma (Mao et al., 2015), cutaneous melanoma (Ladanyi, 2015),
soft tissue sarcoma (Szkandera et al., 2013), and NSCLC (Carus et al., 2013). A recent
analysis of 22 immune populations across human malignancies demonstrated that
polymorphonuclear cell signatures emerged as the most significant adverse cancer-wide
prognostic populations (Gentles et al., 2015).
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These data raised an important question. If PMN-MDSCs have such strong pro-tumorigenic
activity, then why is their recruitment limited? We believe that this mechanism is employed
to limit strong inflammation at early stages of tumor development. PMN-MDSC, with their
immune suppressive and pro-tumorigenic activity, are developed in response to tumorderived factors and are a feature of a more advanced stage of cancer. In early stages, PMNMDSC usually are not detected. Therefore, high expression of granulocytic chemokines may
result in strong infiltration of neutrophils in the tumor microenvironment. Activated
neutrophils are known to have some antitumor activity (Challacombe et al., 2006; Sionov et
al., 2015), and their massive recruitment may be detrimental for tumors.

Author Manuscript

Our data suggest that the CSF1 granulocytic chemokine network can be exploited for
therapeutic purposes. Combining CSF1R and CXCR2 inhibitors reduced the presence of
both populations (TAM and PMN-MDSC) in tumor site. In contrast to a lack of antitumor
effect of each inhibitor alone, combination treatment significantly reduced tumor growth.
Moreover, it dramatically enhanced the effect of immunotherapy with PD-1 antibody. This
may open an opportunity for therapeutic intervention.
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STAR METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the
corresponding author Dmitry Gabrilovich (dgabrilovich@wistar.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Author Manuscript

Human subjects and samples—Samples of peripheral blood and tumor tissues were
collected from patients at Helen F. Graham Cancer Center and University of Pennsylvania.
The study was approved by Institutional Review Boards of the Christiana Care Health
System at the Helen F. Graham Cancer Center, University of Pennsylvania and The Wistar
Institute. All patients signed approved consent forms. Peripheral blood (PB) and tumor
tissues were collected at Helen F. Graham Cancer Center from 11 patients with previously
untreated stage II-III non-small cell lung cancer (NSCLC), 8 patients with stage III-IV
breast cancer, and 6 patients with stage III-IV colon adenocarcinoma. This cohort includes
14 females and 11 males, aged 48–74 years. Human fibroblasts were isolated from resected
lung tissues from NSCLC patients.
Tissue Microarrays (TMA) were prepared, validated, and clinically annotated by Helen F.
Graham Cancer Center tissue procurement and pathology department. Using the Quick-Ray
Manual Tissue Mircoarrayer, each patient was selected and approved by a pathologist and
later validated by three quality control evaluations. TMAs contained samples from 58
patients with pathologically confirmed head and neck cancer.
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Tumor secretomes were prepared from fresh specimens that were stored on wet ice in RPMI
cell culture media and were processed within 24 hr of collection. The tissue sample was
minced into 1 × 1 mm slices and incubated in RPMI cell culture media at 37°C for 4h. After
incubation, the tumor tissue was pelleted at 500 × g for 2 min at 4°C. The RPMI containing
the secreted tissue proteins was removed, filtered using a 0.22 μm centrifugal filter unit,
aliquoted, snap frozen, and stored at -80°C until analysis.
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Mice and tumor models—All experiments with mice were approved by The Wistar
Institute Animal Care and Use Committee. The mice were kept under pathogen-free
conditions. C57BL/6 and Balb/c were obtained from Charles River Laboratories. In all
experiments, adult (6–8 weeks old) female mice were used. EL4 thymoma, CT26 colon
carcinoma, Lewis Lung Carcinoma (LLC), 4T1 mammary carcinoma, and B16F10
melanoma were obtained from ATCC. 4662 primary pancreatic tumor cells were derived
from female KPC mouse model. To establish s.c. tumors, 5×105 tumor cells were injected
into mice, which formed a tumor with a 1.5-cm diameter within 2–3 weeks of injection. For
orthotropic models 105 LLC cells were injected i.v. Ret mice were obtained from Dr.
Umansky (German Cancer Center, Heidelberg, Germany). TRAMP mice were bred in Dr. L.
Languino laboratory (Thomas Jefferson University)
CSF1R inhibitor, JNJ-40346527 (Janssen) was administered at dose 20 mg/kg 6 days per
week p.o. As a control, mice treated with vehicle alone (0.5% HPMC, hydroxypropyl methyl
cellulose, dissolved in water) were used. CXCR2 antagonist SB225002 (Tocris Bioscience)
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was administered at dose 2mg/kg 6 days a week i.p. Treatment was started next day after
tumor injection and continued until the mice were sacrificed. For the treatment with CD115
antibody, it was obtained from Bioxcell (Clone: AFS98) and administered twice a week for
3 weeks at dose 250 μg per mouse. The treatment with anti-PD-1 ab (100 μg; twice a week;
clone RMP1–14, BioXcell) was started 1 week after tumor injection. Entinostat (10 mg/kg,
p.o; Syndax Phermaceuticals) was administered daily for 10 days starting from day 15 after
tumor inoculation.
METHOD DETAILS

Author Manuscript

Cell isolation and culture—Single-cell suspensions were prepared from spleen and BM
followed by red blood cell removal using ammonium chloride lysis buffer. Single-cell
suspensions from tumor tissues were prepared using Mouse Tumor Dissociation Kit
according to the manufacturer’s recommendation (Miltenyi). HPC-enriched cells were
purified from BM using kit from Miltenyi. Cells were then cultured in the presence of 20
ng/ml recombinant GM-CSF (Invitrogen) in RPMI (Biosource International) supplemented
with 10% FBS, 5 nM glutamine, 25 mM HEPES and 1% antibiotics (Invitrogen). 20% v/v
tumor explant supernatant from B16-F10 and LLC tumors were used in some experiments.
To obtain the single cell suspensions, human solid tumor tissues were subjected to an hour of
enzymatic digestion using 0.1 mg/ml hyaluronidase (Sigma-Aldrich), 2 mg/ml collagenase
(Sigma-Aldrich), 600 U/ml DNase (Sigma-Aldrich), and 0.2 mg/ml protease (SigmaAldrich) in RPMI 1640. The digested tissue was passed through a 70-μm mesh, and
erythrocytes were removed by hypotonic lysis and washed thoroughly to remove debris.
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For fibroblast isolation, resected lungs were chopped into pieces, followed by incubation
with collagenase cocktail (250 ug/ml collagenase I, II, and IV in DMEM) on rotator for ~1–
2 hr. The collagenase treatment was quenched by 10% FCS DMEM, cells were filtered,
washed with PBS and incubated in complete media overnight. Next day, the monolayer was
washed several times and fresh media was added for next 4 days until the cells were ready
for treatment.
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Flow cytometry—Antibodies specific for the mouse cell surface markers CD11b, Ly6C,
Ly6G, Gr1, CD45, CD326 (EPCAM), and CD140a (PDGFRa) and for the human cell
surface markers CD11b, CD14, CD33, CD15, CD3, and HLA-DR were purchased from BD
Biosciences. Anti-human CD163 and CD115 antibodies were purchased from Biolegend,
anti-human FAP and anti-mouse CXCR2 antibodies – from R&D Systems. F4/80 and
CD115 were purchased from eBiosciences. The flow cytometry data were acquired using
BD LSRII flow cytometer and analyzed by FlowJo Software (Tree Star).
qRT-PCR—RNA was extracted using total RNA extraction kit (Omega Bio-tek). cDNA
was synthesized using cDNA reverse transcriptase kit (Applied Biosystems) and qPCR was
performed in triplicates using 10 μl of SYBR Master Mixture (Applied Biosystems). The list
of primers’ is attached in Supplemental Figs.
Immunofluorescence and immunohistochemistry—Mouse Tumor tissues were
snap-frozen and slides were fixed with acetone and blocked for 30 min with 5% BSA
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containing Fc block (1:100dilution) in 1X PBST. The primary antibody (Ly6G; clone 1A8;
BD Biosciences) was used at 1:100 dilutions for 1 hr at RT, whereas the secondary antibody
(AF 594; goat anti-rat; Life Technologies) was used at 1:400 dilution. Nuclei were stained
using DAPI (1: 5000 dilutions in PBS, Life technologies). Images were obtained using Leica
TCS SP5 Confocal microscope. During imaging, the gain (voltage), laser intensity settings
and imaging parameters were kept constant between all the samples. Cell number was
calculated per mm2.
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Paraffin-embedded human tissue microarray sections were deparaffinized and rehydrated,
followed by heat-induced antigen retrieval. For immunofluorescence staining, mouse
monoclonal anti-human CD15 (BD Biosciences) and rabbit polyclonal anti-human LOX-1
(Abcam) antibodies were used. Goat anti-mouse IgG Alexa Fluor 514 and goat anti-rabbit
IgG Alexa Fluor 647 (Life Technologies) antibodies were used as secondary antibodies. Cell
nuclei were stained with DAPI (Life Technologies). Imaging was performed using a Leica
TCS SP5 confocal microscope. Sixteen frames acquired with a 63X objective lens were used
to calculate the cell count per mm2. For immunohistochemistry staining of human M-CSF,
tissue microarray sections were incubated with primary antibody, rabbit polyclonal antihuman M-CSF (Abcam). Biotinylated goat anti-rabbit IgG, Avidin/Biotin block kit, ABC
HRP kit, and DAB substrate kit (Vector Laboratories) were used for detection and
visualization.
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H-score method was used to evaluate the percentage of positive stained cells and staining
intensity. Average intensity of staining in positive cells was assigned as an intensity score (0
= none; 1 = weak; 2 = moderate; 3 = strong). The score was obtained by the formula: 3 x
percentage of strongly stained cells + 2 x percentage of moderately stained cells + 1 x
weakly stained cells.
Generation of CSF1 KO tumor line using CRISPR-Cas9—Murine csf-1 gene (gene
ID number 12977) was used as target to design DNA guides. The three isoforms of the
murine gene were compared and a homologous region at the beginning of the gene sequence
was chosen. From this region, the 120-nucleotide sequence 3731 to 3853, that belongs to a
CDS common in all three were selected:
acatggctgggctcccggctgctgctggtctgtctcctcatgagcaggagtattgccaaggaggtgtcagaacactgtagccacatg
attgggaatggacacctgaaggtcctgcagcag
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This sequence was introduced in the Massachusetts Institute of Technology software
CRISPR Design and six guides with low frequency of off-site sites were selected. These
guides were synthetized as pairs of annealed oligos with overhangs cohesive to the digestion
product of BmsBI restriction enzyme. Oligoduplexes were ligated to the vector
pLentiCRISPRv2 and transformed to Stbl3 bacteria. pLentiCRISPRv2 vectors containing
the sgRNA guides were transfected with pMD2.G and pSPAX2 to 293T cells in order to
produce lentiviral vectors. After 24 hr’ incubation, supernatants were collected, filtered
through a 0.45um filter and added to monolayers of LLC tumor cells. Lentiviral vectors
were produced from a pLentiCRISPRv2 plasmid without the sgRNA guides. Three days
later, 3 ug/ml of puromycin was added to the culture and knock out of csf-1 was detected by
ELISA.
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ELISA—The expression levels of CXCL1, CXCL12, CXCL8 or CSF1 in supernatants, cell
lysates or tumor cell lysates were evaluated using ELISA kit as per manufacturers’
instructions (R&D Biosystems).
Primers are provided in Table S1 related to STAR Methods
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Chromatin immunoprecipitation (ChIP) assay: ChIP was performed using the acetylhistone immunoprecipitation assay kit (Millipore). Briefly, histone crosslinking to DNA was
performed by incubating cells with 1% formaldehyde for 10 min at 37°C. Thereafter, cells
were sonicated to shear DNA to an average length of 200–1,000 base pairs, followed by
centrifugation at 13,000 r.p.m. for 10 min. The samples were precleared, with 30 μl of
salmon sperm DNA/Protein A Agarose-50% Slurry for 30 min, and incubated overnight
with primary antibody (acetyl H3/H4, HDAC1 or HDAC2) at 4 °C. The immunocomplexes
were recovered by adding 60 μl of a salmon sperm DNA/Protein A Agarose 50% slurry,
followed by washing, reverse cross-linking with NaCl and recovering DNA by phenol/
chloroform extraction and ethanol precipitation. The DNA was amplified by qPCR using the
primer specific for cxcl1 promoter sequence provided in Key Resources Table.
Lentivirus csf1r shRNA: Lentiviral vectors containing short hairpin RNAi against human
and mouse CSF1R was obtained from Sigma-Aldrich Mission shRNA library (St Louis,
MO, USA) and listed in Key Resources Table.
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Empty vector pLKO.1 was used as control. Lentiviral production was carried out as
described in the protocol developed by the TRC library (Broad Institute). Briefly, 293T cells
were co-transfected with shRNA vector and lentiviral packaging plasmids (pCMVdR8.74psPAX2, pMD2.G). At 36 and 60 hr, the supernatant containing virus was harvested,
and filtered through a 0.45μm filter. For transduction, the cells were layered overnight with
lentivirus containing 8μg/ml polybrene, allowed to recover for 24 hr and then selected using
1μg/ml puromycin.
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Analysis of cell signature in tumor samples: A molecular profiling database of >16,000
primary and >3000 metastatic tumors representing 25 different cancers was developed in a
collaboration between collaboration between Merck & Co., Inc., Kenilworth, NJ USA
andthe H. Lee Moffitt Cancer Center, Tampa, FL. All tumor samples were profiled on a
standardized platform, Affymetrix Custom GeneChip that measures the expression of
~60,000 transcripts. Tissues were processed and accessed for RNA quality according to the
Moffitt Cancer Center’s Total Cancer Care (TCCTM) protocol prior to expression analysis.
Samples were amplified and labeled using a custom automated version of the NuGEN
Ovation WB protocol. Hybridization, labeling and scanning using Affymetrix ovens, fluidics
stations and scanners following the protocols recommended (NuGEN). Hybridization of
affymetrix chips was done following the standard Affymetrix protocol. Generated .CEL files
were then processed using the RMA algorithm as implemented in Affymetrix Power Tools
(APT) package, using default settings and standard CDF file. Generated probeset intensities
were then log10-transformed. Cell fraction deconvolution for neutrophils and monocytes cell
types were generated as described (Newman et al., 2015).
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Statistical analyses were performed using 2-tailed Student’s t test or Mann-Whitney U test
and GraphPad Prism 5 software (GraphPad Software Inc.). Paired t test was used since data
were normally distributed. All the data are presented as mean ± SD and p value less than
0.05 was considered significant. The tumor growth kinetics was assessed in two-way
ANOVA test. The tumor volumes measured over time were used to reflect the tumor growth
trend affected by different treatments. The velocities of tumor growth were compared
between the treatments using a linear mixed-effect model with the random effect at
individual animal level.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
Inhibitors of CSF1R have demonstrated the potent ability to deplete tumor associated
macrophages (TAM). However, they have not had antitumor effects in mice and have
failed in several clinical trials. In this study, we have identified a cross-talk in the tumor
microenvironment that may explain therapeutic limitations of CSF1R inhibitors. CSF1
produced by tumor cells represses the production of granulocytic chemokines by
carcinoma associated fibroblasts and thus limits granulocyte recruitment. Inhibition of
CSF1R reversed this effect and caused substantial accumulation of tumor promoting
polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). The combination of
CSF1R inhibitor with CXCR2 inhibitor, which prevents PMN-MDSC migration,
significantly reduced tumor growth. Moreover, when PD-1 antibody added to this
combination, it resulted in block of tumor growth.
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Highlights
•

PMN-MDSC infiltration of tumors is controlled by carcinoma associated
fibroblasts;

•

CSF-1 silences expression of granulocytic chemokines by CAF mediated by
HDAC2;

•

Inhibition of CSF-1R induced tumor infiltration by PMN-MDSC;

•

Combination of CSF-1R with CXCR2 inhibitors demonstrated strong
antitumor effect
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Figure 1. Effect of CSF1R inhibitor on tumor infiltration by PMN-MDSC
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A. Effect of JNJ-40346527 treatment on tumor growth in different tumor models.
JNJ-40346527 was administered 6 days a week orally (20 mg/kg) from one day after tumor
inoculation and continued until end of observation. Tumors size in mm2 is shown. Each
group included 5–9 mice. Means and SD are shown. B–D. The proportion of cells in tumors
from mice at the end of the treatment as described in Fig. 1A. Each group included 5–8
mice. Means and SD are shown. * - p<0.05, **- p<0.01, *** - p<0.001 in Student’s t-test
from vehicle control group. B. CD11b+Gr-1−F4/80hi TAM. C. CD11b+Ly6ChiLy6G−
monocytic cells. D. CD11b+Ly6CloLy6G+ granulocytic cells. E. Immune suppressive
activity of Ly6G+ cells isolated from tumors of JNJ-40346527 treated mice. Ly6G+ cells
were added at indicated ratios to splenocytes from Pmel transgenic mice and stimulated with
cognate peptide. Proliferation was measured by 3H-thymidine incorporation in triplicates.
Two experiments with the same results were performed. **- p<0.01, *** - p<0.001 in
Student’s t-test from splenocytes alone. F. The absolute number of myeloid cells per gram
tumor of JNJ-40346527 treated mice in indicated tumor models. See also Figures S1.
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Figure 2. CSF1R inhibitor causes recruitment of PMN-MDSC to tumors
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A. The proportion of CD11b+Ly6CloLy6G+ PMN-MDSC in different tissues of mice treated
with JNJ-40346527 at the end of the treatment. Each group included 3–4 mice. * - p<0.05 in
Student’s t-test from vehicle only group. B. Proportion of myeloid cells in tumors evaluated
at different time during the treatment of LLC-TB mice with JNJ-40346527. Each group
included 4 mice. Mean and SD are shown. * - p<0.05 from vehicle control group. C–D. The
proportion and absolute number of PMN-MDSC of LLC-TB mice treated with
JNJ-40346527. in spleen (C) in BM (D) E–F Proportion and absolute number of M-MDSC
of LLC-TB mice treated with JNJ-40346527 in spleen (E) in BM (F) Mean and SD are
shown (n=4). * - p<0.05 from vehicle control group. See also Figures S2 and S3.
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Figure 3. Granulocytic chemokines in tumors of CSF1R inhibitor treated mice
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A and B. Expression of mRNA (by qPCR) of indicated chemokines in tumor tissues treated
with JNJ-40346527 for 16 days or 2 weeks respectively. LLC-TB mice (A) TRAMP mice
(B) Mean and SD (n=3) are shown. * - p<0.05 in Student’s t-test from vehicle control group.
C. Amount of Cxcl1 (measured in lysates by ELISA) in tumors of mice treated with
JNJ-40346527 for 9, 16 or 23 days as described. Mean and SD (n=4) are shown * - p<0.05;
** - p<0.01 in Student’s t-test from vehicle control group. D. Endogenous level of Cxcl1
measured in lysates by ELISA in different cells isolated from tumors of LLC-TB mice.
Fibroblasts – PDGFRa+ cells, tumor cells – CD45-EPCAM+, myeloid cells – CD45+CD11b
+. Mean and SD are shown. * p<0.05; *** p<0.001 in in Student’s t-test from fibroblasts
values. E. Cxcl1 in different cells isolated from tumors of LLC-TB mice treated with
JNJ-40346527 for 16 days. ** - p<0.01 in Student’s t-test from vehicle control group (n=3).
F. Cxcl-1 in fibroblasts isolated from tumors of LLC-TB mice treated with CD115 antibody
twice a week for 3 weeks. *** - p<0.001 in Student’s t-test from vehicle control group
(n=3). G. Cxcl1 expression by qPCR in pancreatic ductal adenocarcinoma treated with FAP
specific CAR T-cells. Tumors were collected 3 days after the injection of second dose of
CAR T-cells. * - p<0.05 from control (n=4). H. Ly6G+ cells in tumor tissues of mice treated
with FAP CAR-T cells with atypical staining (red – Ly6G, blue-DAPI), scale bar = 50 μm
and quantitative results shown (n=4). ** - p<0.05 in Student’s t-test from control. I. Ly6G+
cells per mm2 in tumor tissues of mice treated with FAP CAR-T cells. Tumors were
collected 3 days after CAR-T cell injection. * - p<0.05 in Student’s t-test from control (n=4).
J. Cxcl1 expression (by qPCR) in AE17.ova mesothelioma tumors from mice treated with
FAP specific CAR-T cells. * - p<0.05 from control.
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Figure 4. Effect of CSF1 on fibroblasts’ ability to recruit PMN-MDSC
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A. Expression of CD115 on the surface of fibroblasts tested by FACs and in cell lysates of
cultured CAF tested by western blot B. Expression of Cxcl1 mRNA (qPCR) (left) and
Cxcl-1 protein (ELISA) (right) in normal lung fibroblasts treated with Csf1 with and without
JNJ-40346527. Mean and SD are shown (n=3). **- p<0.01, *** - p<0.001 in Student’s t-test
from control group. C. Effect of Csf1 on fibroblast-mediated recruitment of BM PMNMDSC. Chemotaxis of BM PMN-MDSC from LLC-TB mice was evaluated against
supernatants obtained from fibroblasts cultured with Csf1 and Csf1R inhibitor. *- p<0.05 in
Student’s t-test from control group (n=4). D. PMN-MDSC chemotaxis to supernatants from
fibroblasts in presence of neutralizing Csf1 antibody (Ab). *- p<0.05 from control group in
Student’s t-test (n=3). E. PMN-MDSC chemotaxis to supernatants from fibroblasts in
presence of neutralizing CXCL1 Ab. **-p<0.01 from control group in Student’s t-test. F.
PMN-MDSC chemotaxis to recombinant CXCL1 (100 ng/ml) in the presence of Csf1 and
CSF1R inhibitor ***- p<0.001 in Student’s t-test from control group (n=3). G. Csf1 ELISA
with TES collected from control or JNJ-40346527-treated LLC TB mice. *- p<0.05 in
Student’s t-test from control group (n=4). H. PMN-MDSC chemotaxis in presence of TES
collected from control or JNJ-40346527-treated LLC TB mice. *- p<0.05 in Student’s t-test
from control group (n=4). I. LLC tumor growth kinetics in WT and CXCR2 KO mice with
or without JNJ-40346527 treatment for indicated days. J. The absolute counts of PMNMDSC and TAM in tumors of WT or CXCR2 KO TB mice treated with JNJ-40346527. *p<0.05 in Student’s t-test from control group (n=4). See also Figure S4.
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Figure 5. Effect of CSF1 on fibroblasts
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A. Presence of myeloid cells in LLC tumors with deleted CSF1. WT and CSF1 deleted
tumors were collected from mice 4–5 weeks after inoculation. Mean and SD are shown
(n=4). *- p<0.05 from WT tumors. B. Expression (Means and SD) of chemokines mRNA
(by qPCR) in these tumors. *- p<0.05, ***-p<0.001 in Student’s t-test from respective
controls. C. PMN-MDSC chemotaxis in the presence of fibroblasts treated with supernatants
from WT or CSF1 KO LLC. **-p<0.01 in Student’s t-test from control group (n=3). D.
Supernatants were collected from fibroblasts with silenced csf1r expression (CSF1R
shRNA) treated for 4 days with CSF1. Supernatants were used in chemotaxis of BM PMNMDSC (n=3). *** - p<0.001 in Student’s t-test from control. E. Fibroblasts transduced with
control or Csf1r shRNA were mixed at 1:1 ratio with LLC tumor cells and injected s.c. to
mice. Twelve days later, the presence of myeloid cells in tumors was evaluated (n=4). Mean
and SD are shown ** - p<0.01 in Student’s t-test from control. F. Expression of CSF1R
(CD115) on cells in tumor microenvironment (CD3 T cells, FAP fibroblasts, CD163
macrophages) from 4 different patients. GeoMean is shown. G. Fibroblasts isolated from
resected lung tissues of patients with NSCLC were treated for 4 days with CSF1 followed by
JNJ-40346527 for additional 2 days. Expression of CXCL8 by qPCR (n=3) Mean and SD
are shown. ** - p<0.01 in Student’s t-test from control. H. Migration of peripheral blood
donor’s neutrophils to supernatants from fibroblasts cultured with CSF1 and CSF1R
inhibitor (n=3), * - p<0.05 from control. Means and SD are shown. I. Peripheral blood
donor’s neutrophils chemotaxis to supernatants from fibroblasts in presence of CXCL8
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neutralizing antibody (n=3). * - p<0.05 in Student’s t-test from control. Means and SD are
shown. See also Figures S4 and S5
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Figure 6. Association between CSF1 and PMN-MDSC recruitment to human tumors
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A. Effect of CSF1R expression silencing in human fibroblasts on their ability to induce
neutrophil migration. CSF1R was silenced in human fibroblasts using lentiviral shRNA
construct and then cells were treated with CSF1 for 5 days. Supernatant was used in
chemotaxis of donor peripheral blood neutrophils. Control – fibroblasts infected with
lentivirus containing empty vector or the construct which did not down-regulate CSF1R.
(n=3), ** - p<0.01 in Student’s t-test from control. Mean and SD are shown. B. Migration of
peripheral blood donor’s neutrophils to recombinant CXCL8 (100 ng/ml) in the presence
CSF1 and CSF1R inhibitor. Mean and SD are shown. n = 3. *- p<0.05 from control group.
C–G. Evaluation of the proportion of tumor PMN-MDSC and M-MDSC and amount of
cytokines in tumors of cancer patients. Values of individual tumor samples are plotted. The
proportion of intratumoral CD11b+CD14−CD15+ PMN-MDSC among CD45+ cells
evaluated by flow cytometry. CXCL8 in tumor cell lysates was measured by ELISA and split
based on median (7.84 pg/μg) (C). CD14+HLA-DR−/lo M-MDSC among CD45+ cells (D).
The proportion of PMN-MDSC in tumor samples split based on the amount of CSF1 present
(median 7.5 pg/μg) (E). M-MDSC in samples split based on CSF1 amount in tumors (F).
Amount of CXCL8 in tumor samples split based on CSF1 median (G). Mean and SD are
shown. p values in Student’s t-test are shown on the graphs. H. Correlation between the
amount of CSF1 and CXCL8 proteins in secretomes from 15 ovarian tumors (top panel).
Spearman correlation coefficient was calculated. Analysis of the same samples based on
median of CSF1 amount (bottom panel). Mean and SD are shown. p values in Student’s ttest I. Survival of patients with HNC based on the number of PMN-MDSC (CD15+LOX-1+)
in tumor tissues. TMA contained samples from 58 patients with pathologically confirmed
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HNC. Median of PMN-MDSC presence per mm2 in all samples was 50. Survival log rank
test was used. J. The number of PMN-MDSC in tumor tissues (per mm2) in TMA samples
divided based on median score of M-CSF staining (160). K. Correlation between neutrophil
and monocyte gene signatures in tumor samples (19,000 samples from Merck & Co., Inc.,
Kenilworth, NJ USA database) and expression of CSF1 and CSF2. **** - p<0.00001
calculated between indicated pairs. Mann-Whitney U test was used. The box-and-whisker
plots are show. The box shows the median as well as 25th and 75th percentile. The whiskers
stretch to the maximum and minimum values of that variable. See also Figure S6.
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Figure 7. The mechanisms regulating inhibition of chemokines production by CSF1
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A. mRNA for Cxcl1 (by qPCR) (left) and Cxcl1 protein by ELISA (right) in mouse
fibroblasts cultured for 6 days with CSF1 in the presence (during last three days of culture)
of class I HDAC inhibitor entinostat. Mean and SD (n=3) are shown. ***-p<0.001 in
Student’s t test from control. B–F. The effect of entinostat in vivo. LLC TB mice were
treated with entinostat (10 mg/kg, p.o.) daily for 10 days starting from day 15 after tumor
inoculation. Expression of mRNA for chemokines (qPCR) in tumor tissues. **-p<0.01 in
Student’s t test from control (n=3) (B). Tumor cells were isolated at the end of the treatment
and the amount of CSF1 was measured by ELISA (n=6) (C). CAF were sorted from tumor
tissues and the amount of Cxcl1 was measured in cell lysates by ELISA. Mean and SD are
shown. ****-p<0.0001 in Student’s t test from control (n=4) (D). CSF1R amount in CAF
(E). The presence of PMN-MDSC and TAM in tumors of LLC (n=10) and CT-26 (n=3) TB
mice treated with entinostat. Mean and SD are shown *-p<0.05; **-p<0.01 in Student’s t test
from control (F). G. Mouse fibroblasts were treated with CSF1 for 4 days, followed by 2day treatment of entinostat. ChIP of Cxcl1 promoter was performed using acetylated histone
H3 or acetylated histone H4 antibody. The results are expressed as DNA enrichment,
normalized to corresponding input values. Control IgG was used as a negative control (n=3).
H. ChIP of Cxcl1 promoter was performed using HDAC2 specific antibody (n=3).
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Figure 8. Therapeutic targeting of granulocytes and macrophages
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A. Tumor growth in mice treated with JNJ-40346527 (CSF1R inhibitor), SB225002
(CXCR2 inhibitor), or their combination. Mean and SD are shown. Each group included 5
mice. Significance was calculated using two-way ANOVA test. B. The presence of TAM and
PMN-MDSC in B16F10 tumors. **-p<0.01 from control (n=4). C. LLC TB mice were
treated with inhibitors and PD-1 antibody (100 μg twice a week). Mean and SD are shown.
Each group included 4–5 mice. Significance was calculated using a linear mixed-effect
model with the random effect at individual animal level.
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SOURCE

IDENTIFIER

Rat anti-mouse CD11b

BD Biosciences

Cat#557657

Rat anti-mouse Ly6C

BD Biosciences

Cat#560593

Rat anti-mouse Ly6G

BD Biosciences

Cat#553129

Rat anti-mouse Gr1

BD Biosciences

Cat#553127

Mouse anti-mouse CD45.2

BD Biosciences

Cat#552950

Rat anti-mouse CD326

BD Biosciences

Cat#563478

Rat anti-mouse CD140a

BD Biosciences

Cat#562776

Mouse anti-human CD11b

BD Biosciences

Cat#550019

Mouse anti-human CD14

BD Biosciences

Cat#557831

Mouse anti-human CD33

BD Biosciences

Cat#333946

Mouse anti-human CD15

BD Biosciences

Cat#560828

Mouse anti-human CD3

BD Biosciences

Cat#333946

Mouse anti-human HLA-DR

BD Biosciences

Cat#556643

Mouse anti-human CD163

BioLegend

Cat#333617

Mouse anti-human CD115

BioLegend

Cat#347304

Mouse anti-human FAP

R&D Systems

Cat#FAB3715A-025

Mouse monoclonal CXCR2

R&D Systems

Cat#FAB2164P-025

Mouse monoclonal F4/80

eBioscience

Cat#12-4801-82

Anti-human LOX-1

Abcam

Cat#ab126538

InVivoMab anti-mouse PD-1

Bioxcell

Clone#RMP1-14

InVivoMab anti-mouse CSF1R (CD115)

Bioxcell

Clone#AFS98

Mouse CXCL1/KC

R&D Systems

Cat#AF-453

Human CXCL8/IL-8

R&D Systems

Cat#MAB208-100

Mouse M-CSF

R&D Systems

Cat#MAB416-100

Rabbit anti-human M-CSF

Abcam

Cat#ab9693

Anti-HDAC2 CHIP grade

Abcam

Cat#ab7029

Mouse: Csf1r shRNA lentivirus, see METHOD DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_001037859.2-1091s21c1;

Mouse: Csf1r shRNA lentivirus, see METHOD DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_001037859.2-3516s21c1;

Mouse: Csf1r shRNA lentivirus, see METHOD DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_001037859.2-818s21c1;

Mouse: Csf1r shRNA lentivirus, see METHOD DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_001037859.2-1972s21c1

Human: CSF1r shRNA lentivirus, see METHOD
DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_005211.3-3460s21c1,

Human: CSF1r shRNA lentivirus, see METHOD
DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_005211.x-504s1c1,

Antibodies

Bacterial and Virus Strains
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Human: CSF1r shRNA lentivirus, see METHOD
DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_005211.3-1893s21c1,

Human: CSF1r shRNA lentivirus, see METHOD
DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_005211.3-3042s21c1,

Human: CSF1r shRNA lentivirus, see METHOD
DETAILS

Sigma-Aldrich Mission shRNA library
(St Louis, MO, USA)

Type: NM_005211.3-2873s21c1

Empty vector control plasmid DNA, pLKO.1

Sigma-Aldrich

Cat#SHC001

Biological samples
Peripheral blood, tumor tissues, and tissue microarray

Helen F. Graham Cancer Center and University of Pennsylvania

Chemicals, Peptides, and Recombinant Proteins

Author Manuscript

CSF-1R inhibitor, JNJ-40346527

Janssen Inc.

N/A

Entinostat

Syndax Pharmaceuticals

N/A

SB225002

Tocris Biosciences

Cat#2725

Mouse tumor dissociation kit

Miltenyi Biotech

Cat#130-096-730

CXCL-1 recombinant mouse

BioLegend

Cat#573702

CXCL-8/IL-8 recombinant human

R&D Systems

Cat#208-IL-010/CF

GM-CSF recombinant mouse

Invitrogen

Cat#PMC2013

DAPI

Life Technologies

Cat#D1306

Mouse CXCL1/KC DuoSet for ELISA

R&D Systems

Cat#DY453-05

Human CXCL8/IL-8 DuoSet for ELISA

R&D Systems

Cat#DY208-05

Mouse M-CSF DuoSet for ELISA

R&D Systems

Cat#DY416

Chromatin Immunoprecipitation (ChIP) Assay

Millipore

Cat#17-295

EL4 thymoma

ATCC

N/A

CT26 colon carcinoma

ATCC

N/A

Lewis Lung Carcinoma (LLC)

ATCC

N/A

4T1 mammary carcinoma

ATCC

N/A

B16F10 melanoma

ATCC

N/A

Mouse: 4662 pancreatic ductal adenocarcinoma

KPC mouse

N/A

Mouse: C57BL/6

Charles River

N/A

Mouse: Balb/c

Charles River

N/A

Mouse: Ret melanoma model

Dr. Umansky (German Cancer Center,
Heidelberg, Germany)

N/A

Mouse: TRAMP prostate cancer model

Dr. Languino (Thomas Jefferson
University, Philadelphia)

N/A

Primers, see Table S1

This paper

N/A

Cxcl1 promoter FW: 5′GTGCACATAACGCGTGTGAC-3′

This paper

N/A

Cxcl1 promoter RV: 5′TGCTTCGCTGGACAAGTGAC-3′

This paper

N/A

Critical commercial assays

Experimental Models: Mouse Cell Lines

Author Manuscript

Experimental Models: Organisms/Strains

Author Manuscript

Oligonucleotides
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Cxcl1 promoter for ChIP assay FW: 5′GTGCACATAACGCGTGTGAC-3′,

This paper

N/A

Cxcl1 promoter for ChIP assay RV: 5′TGCTTCGCTGGACAAGTGAC-3′

This paper

N/A

GraphPad Software Inc.

N/A

Software and Algorithms
GraphPad Prism 5

Author Manuscript
Author Manuscript
Author Manuscript
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